BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35401705)

  • 1. Cellular Interaction Analysis Characterizing Immunosuppressive Microenvironment Functions in MM Tumorigenesis From Precursor Stages.
    Liu Z; Zhang S; Li H; Guo J; Wu D; Zhou W; Xie L
    Front Genet; 2022; 13():844604. PubMed ID: 35401705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-Cell RNA-seq Analysis Reveals Dysregulated Cell-Cell Interactions in a Tumor Microenvironment Related to HCC Development.
    Liu Z; Zhang S; Ouyang J; Wu D; Chen L; Zhou W; Xie L
    Dis Markers; 2022; 2022():4971621. PubMed ID: 35634447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis.
    Yao L; Jayasinghe RG; Lee BH; Bhasin SS; Pilcher W; Doxie DB; Gonzalez-Kozlova E; Dasari S; Fiala MA; Pita-Juarez Y; Strausbauch M; Kelly G; Thomas BE; Kumar SK; Cho HJ; Anderson E; Wendl MC; Dawson T; D'souza D; Oh ST; Cheloni G; Li Y; DiPersio JF; Rahman AH; Dhodapkar KM; Kim-Schulze S; Vij R; Vlachos IS; Mehr S; Hamilton M; Auclair D; Kourelis T; Avigan D; Dhodapkar MV; Gnjatic S; Bhasin MK; Ding L
    Cancer Res Commun; 2022 Oct; 2(10):1255-1265. PubMed ID: 36969740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
    Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
    Front Immunol; 2021; 12():792609. PubMed ID: 34880879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
    Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
    Front Immunol; 2020; 11():613007. PubMed ID: 33488620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Cell RNA Sequencing Revealed a 3-Gene Panel Predicted the Diagnosis and Prognosis of Thyroid Papillary Carcinoma and Associated With Tumor Immune Microenvironment.
    Chen Z; Wang Y; Li D; Le Y; Han Y; Jia L; Yan C; Tian Z; Song W; Li F; Zhao K; He X
    Front Oncol; 2022; 12():862313. PubMed ID: 35359404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-Stromal Score Signature: Novel Prognostic Tool of the Tumor Microenvironment in Lung Adenocarcinoma.
    Qi X; Qi C; Qin B; Kang X; Hu Y; Han W
    Front Oncol; 2020; 10():541330. PubMed ID: 33072571
    [No Abstract]   [Full Text] [Related]  

  • 10. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
    Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL; Hofmeister CC; Boise LH; Lonial S; Kemp ML; Dhodapkar KM; Dhodapkar MV
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature.
    Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R
    Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression.
    García-Ortiz A; Rodríguez-García Y; Encinas J; Maroto-Martín E; Castellano E; Teixidó J; Martínez-López J
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer.
    Song Y; Sun Y; Sun T; Tang R
    Comb Chem High Throughput Screen; 2020; 23(5):381-391. PubMed ID: 32264809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
    Danziger SA; McConnell M; Gockley J; Young MH; Rosenthal A; Schmitz F; Reiss DJ; Farmer P; Alapat DV; Singh A; Ashby C; Bauer M; Ren Y; Smith K; Couto SS; van Rhee F; Davies F; Zangari M; Petty N; Orlowski RZ; Dhodapkar MV; Copeland WB; Fox B; Hoering A; Fitch A; Newhall K; Barlogie B; Trotter MWB; Hershberg RM; Walker BA; Dervan AP; Ratushny AV; Morgan GJ
    PLoS Med; 2020 Nov; 17(11):e1003323. PubMed ID: 33147277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer.
    Yu L; Ding Y; Wan T; Deng T; Huang H; Liu J
    Front Immunol; 2021; 12():768115. PubMed ID: 34966389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FABP5, a Novel Immune-Related mRNA Prognostic Marker and a Target of Immunotherapy for Multiple Myeloma.
    Jia H; Zhang X; Liu X; Qiao R; Liu Y; Lv S; Zhu H; Wang J; Kong Q; Zhang H; Zhang Z
    Front Med (Lausanne); 2021; 8():667525. PubMed ID: 34249967
    [No Abstract]   [Full Text] [Related]  

  • 18. Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.
    Calcinotto A; Ponzoni M; Ria R; Grioni M; Cattaneo E; Villa I; Sabrina Bertilaccio MT; Chesi M; Rubinacci A; Tonon G; Bergsagel PL; Vacca A; Bellone M
    Oncoimmunology; 2015 Jun; 4(6):e1008850. PubMed ID: 26155424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion.
    Ryu D; Kim SJ; Hong Y; Jo A; Kim N; Kim HJ; Lee HO; Kim K; Park WY
    Clin Cancer Res; 2020 Feb; 26(4):935-944. PubMed ID: 31558476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.